Aarti Drugs Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1h60wwaycspsxzsqt0xetpg4.pdf

Key Takeaways


Revenue & Volume Dynamics

Patil: "What we expect was that the margin should have grown, the gross margin should have grown even more. What happens in the API business, API and spec-chem business is that for every product, it is product specific, for every product there is certain markup in terms of absolute number per kg. So, what we have seen in the last quarter even if we compare it to the historical numbers of that markup, that markup has not been achieved."

Export Markets: Destocking & Recovery

Shah: "Yes, Latin America has suffered a lot due to major problems with dollar interest rates and dollar shortage and third was inventory de-stocking. So, we expect maybe another one quarter after the 2nd Quarter of this year, 2024, we expect demand to come up again, basically."

New Capacity Build-Out

Patil: "At the optimal level, when you go, as per the current market trend, those products are facing EBITDA margins upwards of 18% to 20%. But the thing is, once the capacity is launched, there might be some bit of price war. But still, we feel that 15% to 16% should be easily achievable from the newer products."

Formulation Business Evolution


Margins & Cost Structure


Balance Sheet & Capital Allocation

Patil: "We are very much comfortable to run a debt of around 0.5 to 0.7 in terms of debt-to-equity ratio. We are very much comfortable doing that. So, probably we are not looking for a debt-free Company, but yes, definitely we will keep debt to the minimum level so that it won't hamper, it won't create any cash crunch for the Company anytime in the near future."

Guidance & Commitments

CommitmentSpecificsTimeline
Negative rate varianceShould stop or reduce significantly; slight impact possible in March but not as sharp as December quarterMarch quarter
Dermatology plant operationalFinal stages; operational commencement anticipatedEnd of January 2024
Salicylic acid plant production startFirst week of FebruaryFebruary 2024
Methylamine project commissioningMarch or AprilMarch-April 2024
Saykha greenfield project operationalBy April endApril 2024
Dermatology sales startSome sales expected in Q1 after operationalQ1 FY25
Dermatology capacity ramp-upTarget 2,000 tons/month; ~30-40% utilization in first year; ramp within 6-7 monthsFY25
New capacity utilization exit rate30-40% utilization for new capacitiesFY25 exit
New capacity EBITDA margins15-16% easily achievable; 18-20% at optimal levelsAt 50%+ utilization
Specialty chemicals growth30-40% growth target, contingent on no further negative rate variationFY25
Volume growth target10-15% volume growth including new capacityComing year and further years
Standalone revenue target₹4,000 to ₹4,500 crores from all projectsNo date
Incremental revenue from new projects₹1,000 to ₹1,200 crores at current price levelsNo date
Existing capacity volume growth5-10% volume growth targetNo date
Gross margin improvementCouple of percent improvement if basic markup over RMC cost is restoredNo date
Latin America demand recoveryOne quarter after Q2 2024Q3 2024
USFDA oral oncology auditEU and USFDA audits expectedCalendar year 2024
FY24 CAPEX₹250 cr to ₹300 crFY24

Key Metrics

MetricQ3 FY24
Consolidated revenue₹608 cr, decline of 8.6% YoY
Consolidated EBITDA₹72 cr, margin at 11.8%, improved 100 bps YoY
Consolidated PAT₹37 cr, margin at 6.1%, improved 60 bps YoY
9M FY24 revenue₹1,912 cr, decline of 3.2% YoY
9M FY24 EBITDA₹234 cr, margin at 12.2%, improved 140 bps YoY
9M FY24 PAT₹124 cr, margin at 6.5%, improved 90 bps YoY
Standalone revenue₹540 cr, decline of 13.8% YoY; contributed ~87% of consolidated revenue
Standalone domestic revenueDeclined ~4.5% YoY; domestic market contributed 67% of standalone revenue
Standalone export revenueGrew ~29% YoY; export market contributed 33% of standalone revenue
API volume growth~8.4% YoY
Formulation segment revenue₹79.3 cr, growth of 58.7% YoY; exports contributed ~58%
Formulation segment 9M FY24 revenue₹257 cr, growth of 18.2% YoY
Gross marginImproved ~15-20 bps QoQ
Selling prices vs September 2023~7% lower on aggregate basis
CAPEX incurred 9M FY24~₹162 cr; targeted total CAPEX for FY24: ₹250 cr to ₹300 cr
Debt-to-equity ratio0.47 on consolidated basis; historically 1.4 to 1.5x
Debtor days90 days for December 2023, down from ~100 days in March 2023
Interim dividend₹1 per share recommended by Board
Volume growth target for coming year10% to 15%
Specialty chemical growth target for FY25Around 30% to 40%
Incremental revenue potential from new projects₹1,000 to ₹1,200 cr at current price levels
New capacity utilization expectation for FY2530% to 40%
EBITDA margin expectation from new products15% to 16% initially, upwards of 18% to 20% at optimal utilization
Domestic pricing decline~24% YoY
Domestic volume growthA little more than 20% YoY
Export volume decline~14.5% YoY
Export rate variationAround minus 15